TNF and benign prostatic hyperplasia: Again, these data indicate that methotrexate significantly increases BPH incidence (p < 0.0001) while TNF-antagonists significantly decrease BPH incidence (p = 0.0314) compared to AI patients not taking medication (Supplementary Table 9).